Abstract
Hospitalization, often due to relapse, is the largest component (∼70%) of direct healthcare costs in AML. In the international, placebo-controlled QUAZAR AML-001 trial, Oral-AZA significantly prolonged overall and relapse-free survival in patients with AML in remission. We determined hospitalization rates and durations for all patients in QUAZAR AML-001, and estimate associated hospitalization costs in Sweden and Norway.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
